Theriva Biologics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2005
Selling, General & Admin	7.12	9.86	6.47	5.03	4.58	Upgrade
Research & Development	14.31	11.72	7.8	5.13	11.08	Upgrade
Operating Expenses	21.43	21.58	14.27	10.16	15.66	Upgrade
Operating Income	-21.43	-21.58	-14.27	-10.16	-15.66	Upgrade
Other Expense / Income	-1.44	-0.47	-0.01	-0.12	-0.36	Upgrade
Pretax Income	-19.99	-21.11	-14.27	-10.04	-15.3	Upgrade
Income Tax	-1.64	-1.43	0	0	0	Upgrade
Net Income	-18.35	-19.69	-14.27	-10.04	-15.3	Upgrade
Preferred Dividends	0	0.34	8.92	2.51	0.77	Upgrade
Net Income Common	-18.35	-20.03	-23.19	-12.56	-16.08	Upgrade
Shares Outstanding (Basic)	16	15	12	2	2	Upgrade
Shares Outstanding (Diluted)	16	15	12	2	2	Upgrade
Shares Change	5.09%	25.76%	541.06%	15.65%	163.75%	Upgrade
EPS (Basic)	-1.14	-1.31	-1.90	-6.60	-9.80	Upgrade
EPS (Diluted)	-1.14	-1.31	-1.90	-6.60	-9.80	Upgrade
Free Cash Flow	-19.2	-19.2	-12.9	-12.18	-13.87	Upgrade
Free Cash Flow Per Share	-1.19	-1.25	-1.06	-6.41	-8.44	Upgrade
EBITDA	-19.47	-20.84	-14.18	-9.84	-15.06	Upgrade
Depreciation & Amortization	0.52	0.27	0.09	0.2	0.24	Upgrade
EBIT	-19.99	-21.11	-14.27	-10.04	-15.3	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).